DATE/TIME: May 30, 1:00 – 1:12 PM
TITLE: Psychosocial digital application for caregivers of patients undergoing hematopoietic stem cell transplantation (HSCT): A randomized controlled trial.
LOCATION: S504 | Live Stream
ABSTRACT #: 11000
CO-AUTHOR: Dr. Lara Traeger

DATE/TIME: May 30, 1:00 – 1:15 PM
TITLE: Emerging therapeutics for patients with brain tumors and rare oncogenic drivers
LOCATION: S102 | On Demand
EDUCATION SESSION: Incorporating targeted therapy into neuro-oncology practice
PRESENTER: Dr. Antonio Iavarone

DATE/TIME: May 30, 2:00 – 2:06 PM
TITLE: IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF).
LOCATION: E450a | On Demand
ABSTRACT #: 6515
CO-AUTHOR: Dr. Terrence Bradley

DATE/TIME: May 30, 4:30 – 5:30 PM
TITLE: Oncologic surgeon perspective
LOCATION: S402 | On Demand
CASE-BASED PANEL: Pelvic sarcomas: treatment challenges and outcomes
PANELIST: Dr. Francis Hornicek

DATE/TIME: May 31, 9:06 – 9:12 AM
TITLE: Escalating impact of alcohol-related cancer mortality in the US: A call for action.
LOCATION: E350 | On Demand
ABSTRACT #: 10519
FIRST AUTHOR: Dr. Chinmay Jani
SENIOR AUTHOR: Dr. Gilberto Lopes

DATE/TIME: May 31, 5:24 – 5:36 PM
TITLE: Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in PD1 refractory metastatic melanoma.
LOCATION: Hall D2 | Live Stream
ABSTRACT #: 2508
CO-AUTHOR: Dr. Leonel Hernandez-Aya

DATE/TIME: June 1, 11:15 – 11:21 AM
TITLE: The phase II NIBIT-ML1 study of nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Tumor methylation landscape and correlation with clinical outcomes.
LOCATION: S406 | On Demand
ABSTRACT #: 2512 (late-breaking abstract)
CO-AUTHOR: Dr. Michele Ceccarelli

DATE/TIME: June 1, 11:45 – 11:57 AM
TITLE: Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma.
LOCATION: Hall D2 | Live Stream
ABSTRACT #: 4506
CO-AUTHOR: Dr. Jaime Merchan

DATE/TIME: June 1, 11:45 – 11:57 AM
TITLE: A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).
LOCATION: S100a | Live Stream
ABSTRACT #: 11506
CO-AUTHOR: Dr. Jonathan Trent

DATE/TIME: June 1, 11:57 AM – 12:09 PM
TITLE: Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.
LOCATION: S100a | Live Stream
ABSTRACT #: 11507
CO-AUTHOR: Dr. Gina D’Amato

DATE/TIME: June 1, 11:57 AM – 12:09 PM
TITLE: Romiplostim for chemotherapy induced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: A global, phase 3, randomized, placebo-controlled trial (RCT).
LOCATION: S100bc | Live Stream
ABSTRACT #: 12007
CO-AUTHOR: Dr. Gerald Soff

Event

DATE/TIME: June 1, 9:00 PM
TITLE: Miami Nights, Sylvester’s reception during ASCO
LOCATION: Chicago Cultural Center, G.A.R. Hall, 78 E Washington St., Chicago, IL 60602
RSVP: Sylvester.org/MiamiNights

DATE/TIME: June 2, 9:00 – 9:12 AM
TITLE: Is pancreas subtyping ready for prime time?
LOCATION: Hall D2 | Livestream
CLINICAL SCIENCE SYMPOSIUM: Gastrointestinal cancer—gastroesophageal, pancreatic, and hepatobiliary
PRESENTER: Dr. Peter Joel Hosein

DATE/TIME: June 2, 9:06 – 9:12 AM
TITLE: Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay.
LOCATION: S406 | On Demand
ABSTRACT #: 3016
CO-AUTHOR: Dr. Gilberto Lopes

DATE/TIME: June 2, 4:12 – 4:24 PM
TITLE: A novel virtual reality supportive care intervention (BMT-VR) for patients undergoing hematopoietic stem cell transplantation (HSCT): A pilot randomized clinical trial.
LOCATION: S100bc | Live Stream
ABSTRACT #: 1504
CO-AUTHOR: Dr. Lara Traeger

DATE/TIME: June 3, 10:21 – 10:33 AM
TITLE: Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial.
LOCATION: S100bc | Live Stream
ABSTRACT #: 7503
FIRST AUTHOR: Dr. C. Ola Landgren

DATE/TIME: June 3, 11:09 – 11:21 AM
TITLE: A phase II randomized study of neoadjuvant pembrolizumab (P) alone or in combination with vidutolimod (V) in high-risk resectable melanoma: ECOG-ACRIN EA6194.
LOCATION: S100a | Live Stream
ABSTRACT #: 9505 (late-breaking abstract)
CO-AUTHOR: Dr. Jose Lutzky